Publicacions en què col·labora amb Felipe Prosper Cardoso (11)

2024

  1. An automated network-based tool to search for metabolic vulnerabilities in cancer

    Nature Communications , Vol. 15, Núm. 1

  2. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

  3. G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1

    Cell Death and Disease, Vol. 15, Núm. 11

  4. HDACi vorinostat protects muscle from degeneration after acute rotator cuff injury in mice

    Bone and Joint Research, Vol. 12, Núm. 4, pp. 169-183

  5. Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer

    Cell Death Discovery, Vol. 10, Núm. 1

2023

  1. AG5 is a potent non-steroidal anti-inflammatory and immune regulator that preserves innate immunity

    Biomedicine and Pharmacotherapy, Vol. 169

  2. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

2022

  1. G9a inhibition by CM-272: Developing a novel anti-tumoral strategy for castration-resistant prostate cancer using 2D and 3D in vitro models

    Biomedicine and Pharmacotherapy, Vol. 150

  2. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with in Vivo Efficacy in Multiple Myeloma

    Journal of Medicinal Chemistry, Vol. 64, Núm. 6, pp. 3392-3426

2013

  1. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission

    Clinical Cancer Research, Vol. 19, Núm. 17, pp. 4770-4779